This is not a radical proposal: 20 years ago, the FDA shifted its primary efficacy end point for osteoporosis drugs from bone mineral density (a reasonable surrogate for the risk of fracture) to fractures themselves.

• 这并不是一个激进的提议，早在20年前，FDA就将骨质疏松症的主要疗效结局从观察骨矿物质密度调整为观察骨折。